26/10/2011 - Press release
New guidelines which provide an easy to use checklist for the accurate and ethical reporting of studies involving genetic or molecular risk factors for disease have been proposed by a group of international researchers among them Miquel Porta, head of the group of Clinical and molecular epidemiology of cancer at IMIM (Hospital del Mar Research Institute), and are published in this week’s PLoS Medicine
14/10/2011 - Institutional news
During approximately one month, some twenty professionals of the Anti-Doping Control Laboratory of the IMIM (Hospital del Mar Research Institute) will be moving to Mexico to carry out the tests for anti-doping control at the games.
Més informació "The Pan American Games begin: The Anti- Doping Lab of IMIM moves to Mexico."
13/10/2011 - Press release
The Spanish Society of Cardiology (Sociedad Española de Cardiología or SEC) warns that the percentage of the Spanish population with a good control of cardiovascular risk factors is no higher than, at best, 65%, and at worst, 34%.
06/10/2011 - Press release
Certara , a US-based company and a leader in the provision of translational medicine services and solutions, is set to be the exclusive distributor of the software developed by Chemotargets the first spin-off of the IMIM (Instituto de Investigación Hospital del Mar, 'Hospital del Mar Research Institute') dedicated to the design of new drugs.
19/09/2011 - Press release
A team of researchers from the Hospital del Mar and IMIM, as well as from CIBER for Respiratory Diseases (CIBERES) – Carlos III Health Institute – Ministry of Science and Innovation- has lead a study proving that patients with severe COPD do not present muscular destruction until very advanced stages of the disease, especially when they still maintain a good muscle mass.
12/09/2011 - Press release
The International Consortium for Blood Pressure genome-wide association Studies (ICBP), an international project in which researchers from the IMIM (Hospital del Mar Research Institute) have participated as the only Spanish researchers, has identified 29 loci or genetic characteristics, 16 of which are new, associated with the risk of presenting with high blood pressure in a population of European origin
Més informació "New Leads on the Genetic Origin of High Blood Pressure"
9/09/2011 - Press release
Researchers from the Hospital del Mar Oncology Department and the Cancer Research Programme of its research Institute, the ‘IMIM’, have confirmed the prognostic value of a new therapeutic target, the PARP1 protein, in breast cancer patients. This finding, which was published today in the Annals of Oncology, was achieved in partnership with the Jiménez-Díaz Foundation in Madrid and the Hospital Clínico in Valencia
08/09/2011 - Press release
A major landmark study released a few days ago by the European College of Neuropsychopharmacology (ECNP) in which IMIM (Hospital del Mar Research Institute) has participated, sheds new light on the state of Europe’s mental and neurological health.
06/06/2011 - Press release
Researchers at Hospital del Mar Research Institute (IMIM) and Pompeu Fabra University (UPF) have successfully reproduced and reconstructed the complete process of a small molecule binding with its target protein. This advance enables the drug's affinity and binding level with the protein to be calculated as well as understanding the interactions established by the drug in order to act, thus moving towards safer and more efficient design of new drugs.
Més informació "A major step in molecular simulation - key to designing new drugs"
27/05/2011 - Press release
A new consortium of European organisations unite to support next generation drug discovery by providing a single view across data sources, bringing the semantic web to drug discovery.
Més informació "Semantic 'lego': an information framework to drive drug discovery."
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact